<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab4">
 <label>Table 4</label>
 <caption>
  <p>Interaction between malaria and Ebola drugs with ACE-2 receptor (PDB code = 6M0J)</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Drug</th>
    <th align="left">Ligand</th>
    <th align="left">Receptor</th>
    <th align="left">Interaction</th>
    <th align="left">Distance</th>
    <th align="left">E (kcal/mol)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Atovaquone</td>
    <td align="left">6-ring</td>
    <td align="left">CA VAL 209 (A)</td>
    <td align="left">pi-H</td>
    <td align="left">3.90</td>
    <td align="left">− 1.0</td>
   </tr>
   <tr>
    <td align="left" rowspan="5">Chloroquine</td>
    <td align="left">N 17</td>
    <td align="left">O GLU 208 (A)</td>
    <td align="left">H-donor</td>
    <td align="left">3.16</td>
    <td align="left">− 0.6</td>
   </tr>
   <tr>
    <td align="left">CL 1</td>
    <td align="left">NZ LYS 94 (A)</td>
    <td align="left">H-acceptor</td>
    <td align="left">3.45</td>
    <td align="left">− 0.9</td>
   </tr>
   <tr>
    <td align="left">6-ring</td>
    <td align="left">CA VAL 209 (A)</td>
    <td align="left">pi-H</td>
    <td align="left">4.40</td>
    <td align="left">− 0.5</td>
   </tr>
   <tr>
    <td align="left">6-ring</td>
    <td align="left">CG1 VAL 209 (A)</td>
    <td align="left">pi-H</td>
    <td align="left">4.14</td>
    <td align="left">− 0.6</td>
   </tr>
   <tr>
    <td align="left">6-ring</td>
    <td align="left">N ASN 210 (A)</td>
    <td align="left">pi-H</td>
    <td align="left">3.62</td>
    <td align="left">− 0.6</td>
   </tr>
   <tr>
    <td align="left" rowspan="2">Doxycycline</td>
    <td align="left">O 24</td>
    <td align="left">OE1 GLU 208 (A)</td>
    <td align="left">H-donor</td>
    <td align="left">3.01</td>
    <td align="left">− 1.8</td>
   </tr>
   <tr>
    <td align="left">6-ring</td>
    <td align="left">CG2 VAL 209 (A)</td>
    <td align="left">pi-H</td>
    <td align="left">4.28</td>
    <td align="left">− 0.7</td>
   </tr>
   <tr>
    <td align="left" rowspan="4">Mefloquine</td>
    <td align="left">N 29</td>
    <td align="left">O ASN 210 (A)</td>
    <td align="left">H-donor</td>
    <td align="left">2.91</td>
    <td align="left">− 0.7</td>
   </tr>
   <tr>
    <td align="left">N 29</td>
    <td align="left">N ASN 210 (A)</td>
    <td align="left">H-acceptor</td>
    <td align="left">3.33</td>
    <td align="left">− 0.5</td>
   </tr>
   <tr>
    <td align="left">6-ring</td>
    <td align="left">CB GLU 208 (A)</td>
    <td align="left">pi-H</td>
    <td align="left">4.42</td>
    <td align="left">− 0.5</td>
   </tr>
   <tr>
    <td align="left">6-ring</td>
    <td align="left">CG2 VAL 209 (A)</td>
    <td align="left">pi-H</td>
    <td align="left">4.46</td>
    <td align="left">− 0.6</td>
   </tr>
   <tr>
    <td align="left" rowspan="2">Primaquine</td>
    <td align="left">6-ring</td>
    <td align="left">CG1 VAL 209 (A)</td>
    <td align="left">pi-H</td>
    <td align="left">4.24</td>
    <td align="left">− 0.7</td>
   </tr>
   <tr>
    <td align="left">6-ring</td>
    <td align="left">CG1 VAL 209 (A)</td>
    <td align="left">pi-H</td>
    <td align="left">4.52</td>
    <td align="left">− 0.7</td>
   </tr>
   <tr>
    <td align="left">Tafenoquine</td>
    <td align="left" colspan="5">No measured interaction</td>
   </tr>
   <tr>
    <td align="left">Favipiravir</td>
    <td align="left">O 12</td>
    <td align="left">NZ LYS 94 (A)</td>
    <td align="left">H-acceptor</td>
    <td align="left">3.12</td>
    <td align="left">− 3.5</td>
   </tr>
   <tr>
    <td align="left">Ribavirin</td>
    <td align="left">O 15</td>
    <td align="left">NZ LYS 562 (A)</td>
    <td align="left">H-acceptor</td>
    <td align="left">3.03</td>
    <td align="left">− 3.6</td>
   </tr>
   <tr>
    <td align="left" rowspan="6">Galidesivir</td>
    <td align="left">N 14</td>
    <td align="left">O ASN 210 (A)</td>
    <td align="left">H-donor</td>
    <td align="left">3.05</td>
    <td align="left">− 1.0</td>
   </tr>
   <tr>
    <td align="left">O 29</td>
    <td align="left">CE LYS 562 (A)</td>
    <td align="left">H-acceptor</td>
    <td align="left">3.16</td>
    <td align="left">− 0.7</td>
   </tr>
   <tr>
    <td align="left">5-ring</td>
    <td align="left">CA VAL 209 (A)</td>
    <td align="left">pi-H</td>
    <td align="left">3.79</td>
    <td align="left">− 2.1</td>
   </tr>
   <tr>
    <td align="left">6-ring</td>
    <td align="left">CA VAL 209 (A)</td>
    <td align="left">pi-H</td>
    <td align="left">4.40</td>
    <td align="left">− 0.5</td>
   </tr>
   <tr>
    <td align="left">5-ring</td>
    <td align="left">N ASN 210 (A)</td>
    <td align="left">pi-H</td>
    <td align="left">4.25</td>
    <td align="left">− 2.7</td>
   </tr>
   <tr>
    <td align="left">6-ring</td>
    <td align="left">ND2 ASN 210 (A)</td>
    <td align="left">pi-H</td>
    <td align="left">4.58</td>
    <td align="left">− 1.3</td>
   </tr>
   <tr>
    <td align="left" rowspan="2">Brincidovir</td>
    <td align="left">O 63</td>
    <td align="left">OE2 GLU 208 (A)</td>
    <td align="left">H-donor</td>
    <td align="left">2.79</td>
    <td align="left">− 6.4</td>
   </tr>
   <tr>
    <td align="left">O 74</td>
    <td align="left">NE2 GLN 98 (A)</td>
    <td align="left">H-acceptor</td>
    <td align="left">3.01</td>
    <td align="left">− 1.2</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
